Sugi Predict

Sugi Predict / Compounds / SCHEMBL668966

SCHEMBL668966

SCHEMBL668966

CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SERPINA6 P08185 3/20 1.00
▸ CYP3A4 P08684 6/20 0.72
▸ SMN1; SMN2 Q16637 6/20 0.72
▸ LMNA P02545 5/20 0.72
▸ ALDH1A1 P00352 5/20 0.72
▸ TSHR P16473 3/20 0.72
▸ NR3C2 P08235 3/20 0.72
▸ CYP2C9 P11712 2/20 0.72
▸ HIF1A Q16665 2/20 0.72
▸ MAPT P10636 2/20 0.72
▸ MAPK1 P28482 2/20 0.72
▸ NR3C1 P04150 2/20 0.72
▸ SHBG P04278 2/20 0.72
▸ PMP22 Q01453 2/20 0.72
▸ CYP2C19 P33261 1/20 0.72
▸ KDM4E B2RXH2 1/20 0.72
▸ MEN1 O00255 1/20 0.72
▸ SLC22A2 O15244 1/20 0.72
▸ SLC22A1 O15245 1/20 0.72
▸ NR1I2 O75469 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15920543 1.00 SERPINA6 (1.00) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL14420894 1.00 SERPINA6 (1.00) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL14525642 1.00 SERPINA6 (1.00) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL15904593 1.00 SERPINA6 (1.00) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL9348234 0.92 SERPINA6 (0.85) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL18927106 0.92 SERPINA6 (0.85) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL9348241 0.92 SERPINA6 (0.85) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL6347180 0.91 SERPINA6 (0.84) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL31095098 0.90 SERPINA6 (0.82) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1
SCHEMBL5497592 0.89 SERPINA6 (0.80) SERPINA6CYP3A4SMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250041208-A1 NEW INJECTABLE COMBINATION FORMULATION NANEXA AB (SE) 2025-02-06 — — US claimed
CN-119125361-A Rapid detection method for 27 steroid hormones in mangrove plants 中国科学院南海海洋研究所 2024-12-13 — — CN claimed
EP-4456874-A1 FAST ACTING JOINT HEALTH COMPOSITION AND USE THEREOF Lonza Greenwood LLC (US) 2024-11-06 — — EP claimed
EP-4444277-A1 NEW INJECTABLE COMBINATION FORMULATION Nanexa AB (SE) 2024-10-16 — — EP claimed
CN-118647367-A Novel injectable combination formulations 南爱克萨股份公司 2024-09-13 — — CN claimed
CN-118271381-A New process for preparing prednisone and other series corticosteroids from progesterone 天津药业研究院股份有限公司 2024-07-02 — — CN claimed
CN-114075259-B Recovery method of cortisone acetate mother liquor 保定九孚生化有限公司 2024-04-12 — — CN claimed
CN-117683072-A Synthesis process of 6-methyl Grignard hydrolysate 台州仙琚药业有限公司 2024-03-12 — — CN claimed
EP-4262982-A1 COMPOSITIONS FOR EFFECTIVE MANAGEMENT OF FIBROBLAST- LIKE SYNOVIOCYTES MEDIATED RHEUMATOID ARTHRITIS Sami-Sabinsa Group Limited (IN) 2023-10-25 — — EP claimed
WO-2023150113-A1 FAST ACTING JOINT HEALTH COMPOSITION AND USE THEREOF LONZA GREENWOOD LLC (US) 2023-08-10 — — WO claimed
US-20050118263-A1 Composition UNIVERSITY OF EDINBURGH, THE (GB) 2005-06-02 — — US claimed
US-20050032761-A1 Lipid profile modulation EDINBURGH, THE UNIVERSITY OF (GB) 2005-02-10 — — US claimed
US-20050020550-A1 Selective testicular 11beta-HSD inhibitors and methods of use thereof MORRIS DAVID J (US) 2005-01-27 — — US claimed
EP-1492541-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR AND A DIURETIC AGENT THE UNIVERSITY OF EDINBURGH (GB) 2005-01-05 — — EP claimed
WO-2004097002-A2 SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF THE MIRIAM HOSPITAL (US) 2004-11-11 — — WO claimed
EP-1420769-A2 LIPID PROFILE MODULATION WITH STEROIDS THE UNIVERSITY OF EDINBURGH (GB) 2004-05-26 — — EP claimed
WO-2003086410-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR AND A DIURETIC AGENT THE UNIVERSITY OF EDINBURGH (GB) 2003-10-23 — — WO claimed
US-20030148987-A1 Therapy of glucocorticoid associated state in by administering 11 beta -HSD1 reductase inhibitor selected from 11-keto-testoterone, 11-keto- androsterone, 11-keto-pregnenolone, 11-keto-dehydro- epiandrostenedione etc. RHODE ISLAND HOSPITAL 2003-08-07 — — US claimed
WO-2003059267-A2 SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF RHODE ISLAND HOSPITAL (US) 2003-07-24 — — WO claimed
WO-2002076435-A2 LIPID PROFILE MODULATION WITH STEROIDS THE UNIVERSITY OF EDINBURGH (GB) 2002-10-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020550-A1 Selective testicular 11beta-HSD inhibitors and methods of use thereof HSD17B11, HSD11B1, HSD17B1 SERPINA6 454/4885CYP3A4 398/4885SMN1; SMN2 2493/4885
US-20030148987-A1 Therapy of glucocorticoid associated state in by administering 11 beta -HSD1 reductase inhibitor selected from 11-keto-testoterone, 11-keto- androsterone, 11-keto-pregnenolone, 11-keto-dehydro- epiandrostenedione etc. HSD11B1, HSD11B2, HSD17B2 SERPINA6 103/4885CYP3A4 101/4885SMN1; SMN2 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback